Open Access
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
Jama OncologyPeer ReviewedPaolo A. Ascierto +272018Journals
This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors.

The content you want is available to Zendy users.

Already have an account? Sign in
Having issues? Contact support